Market Overview

UPDATE: Bank of America Raises PT to $70 on Baxter International; Gambro Strategic Fit at Steep Price

Share:
Related BAX
Baxter and Baxalta Holdings Outline Vision for Accelerated and Sustainable Growth, Showcase Innovation
Earnings Scheduled For April 23, 2015
Tracking Tweedy Browne Portfolio - Q1 2015 Update (Seeking Alpha)

Bank of America reiterated its Buy rating on Baxter International (NYSE: BAX) and increased its price target from $67 to $70.

Bank of America commented, "On Friday the Wall Street Journal and several other media outlets reported that BAX is in talks to acquire privately held Gambro for $4bn (BAX's market cap is $38bn). Gambro is the #2 share player in the hemodialysis technology market where BAX has little presence, and BAX is #1 in the peritoneal dialysis market where Gambro has no presence. In our view, in the hands of BAX, Gambro would be a much tougher HD competitor and a strong strategic fit, with the potential for significant synergies, but a $4bn price tag creates a very high hurdle for positive returns in our view."

Baxter International closed at $67.18 on Friday.

Latest Ratings for BAX

DateFirmActionFromTo
May 2015BarclaysMaintainsOverweight
Apr 2015BMO CapitalMaintainsOutperform
Apr 2015JP MorganMaintainsNeutral

View More Analyst Ratings for BAX
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (BAX)

Around the Web, We're Loving...